News
CLPT
5.33
-1.11%
-0.06
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 2d ago
CLEARPOINT NEURO CONGRATULATES ITS PARTNER AVIADOBIO ON FIRST PATIENT TREATED IN ITS ASPIRE-FTD CLINICAL TRIAL EVALUATING AVB-101 FOR FRONTOTEMPORAL DEMENTIA WITH GRN MUTATIONS
Reuters · 3d ago
Weekly Report: what happened at CLPT last week (0408-0412)?
Weekly Report · 5d ago
Weekly Report: what happened at CLPT last week (0401-0405)?
Weekly Report · 04/08 11:51
Weekly Report: what happened at CLPT last week (0325-0329)?
Weekly Report · 04/01 11:47
Why ClearPoint Neuro (CLPT) Stock Might be a Great Pick
NASDAQ · 03/27 12:32
Weekly Report: what happened at CLPT last week (0318-0322)?
Weekly Report · 03/25 11:51
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 03/19 13:00
Weekly Report: what happened at CLPT last week (0311-0315)?
Weekly Report · 03/18 11:49
ClearPoint Neuro Price Target Raised to $9.00/Share From $8.00 by Stifel
Dow Jones · 03/13 12:55
Stifel Reiterates Buy on ClearPoint Neuro, Raises Price Target to $9
Benzinga · 03/13 12:45
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 03/13 06:20
Clearpoint Neuro Inc reports results for the quarter ended in December - Earnings Summary
Clearpoint Neuro Inc reports results for the quarter ended in December. Revenue rose 31.6% to $6.81 million from a year ago. The company reported a quarterly adjusted loss of 19 cents per share. The mean expectation of three analysts was for a loss of 20 cents.
Reuters · 03/12 21:52
ClearPoint Neuro, Inc. (CLPT) Reports Q4 Loss, Tops Revenue Estimates
NASDAQ · 03/12 21:40
ClearPoint Neuro: Q4 Earnings Insights
ClearPoint Neuro reported its Q4 earnings of $-0.19 on March 12. The company beat estimates by 5.0%. The company's revenue was up $1.64 million from the same period last year. ClearPoint Neuro is expected to announce its earnings on March 14.
Benzinga · 03/12 20:30
ClearPoint Neuro Unveils Insightful Investor Presentation Update
TipRanks · 03/12 20:25
*ClearPoint Neuro Backs 2024 Rev $28M-$32M >CLPT
Dow Jones · 03/12 20:25
*ClearPoint Neuro 4Q Rev $6.8M >CLPT
Dow Jones · 03/12 20:24
ClearPoint Neuro reports Q4 results
ClearPoint Neuro reports Q4 results. Revenue of $6.8M (+32% Y/Y) beats by $0.27M. Operating expenses for the fourth quarter of 2023 were $8.7 million. Cash burn of $1.2 million.
Seeking Alpha · 03/12 20:10
Press Release: ClearPoint Neuro Reports Fourth -2-
Statements in this press release may include forward-looking statements about the Company's plans, growth and strategies. These statements are based on management's current expectations and are subject to risks and uncertainties. The Company's actual results may differ from those expressed or implied by such statements. The company does not assume any obligation to update these statements.
Dow Jones · 03/12 20:05
More
Webull provides a variety of real-time CLPT stock news. You can receive the latest news about Clearpoint Neuro Inc through multiple platforms. This information may help you make smarter investment decisions.
About CLPT
ClearPoint Neuro, Inc. is a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company provides both clinical products as well as pre-clinical development services for controlled drug and device delivery. The Company’s flagship product is the ClearPoint Neuro Navigation System. Its initial product offering, the ClearPoint system, is an integrated system comprised of capital equipment and disposable products, designed to allow minimally invasive procedures in the brain to be performed in a magnetic resonance imaging (MRI) suite. The ClearPoint Array Neuro Navigation System and its principal disposable component is designed to be deployed in an operating room setting while also being usable in an MRI suite. It is engaged with healthcare and research centers in North America, Europe, Asia, and South America. It also provides solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide.